Table 3.

Scenario analysis using scenarios A and B.

Scenario	Scenario A ($1,038,093)		Scenario B ($1,485,635)
	ICER (QALY)	% Difference	ICER (evLYG)	% Difference
	$150,000	Ref	$150,000	Ref
Durability of 10 years	$352,135	+135%	$364,825	+143%
Durability of 20 years	$190,593	+27%	$200,844	+34%
Durability of 30 years	$162,876	+9%	$167,881	+12%
Constant costs and utilities per health state	$156,329	−4%	$156,722	−4%
evLYG utility of 1.0 during extended survival	$150,000	0%	$134,677	−10%

Note: Scenario A includes a CEA with QALYs and a placeholder treatment cost of $1,038,093. Scenario B includes a CEA with evLYG and a placeholder treatment cost of $1,485,635.

Both scenarios assume 3.0% discounting of costs and benefits.

CEA, cost-effectiveness analysis; evLYG, equal value life years gained; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.